First treatment for spinal muscular atrophy to be submitted for FDA approval based on positive results in clinical trial
A major milestone was reached when nusinersen, an investigational treatment for spinal muscular atrophy (SMA), was shown to significantly improve achievement of motor milestones in babies with infantile-onset SMA.
Leave a Reply